• Adding Antiandrogen to Radiation Therapy Extends Survival in Relapsed Prostate Cancer
  • Venetoclax plus Rituximab an Attractive Treatment Option for Relapsed or Refractory CLL
  • Aggressive Local Consolidative Therapy Shows Benefit in Patients with Oligometastatic Non–Small-Cell Lung Cancer
  • Lutetium-177-Dotatate Extends Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors
  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Two-Drug Combination Shows Promise for Recurrent Small-Cell Lung Cancer
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
  • Afatinib Superior to Gefitinib as First-Line Treatment for EGFR Mutation–Positive NSCLC
  • Combination Chemotherapy plus Radiation Prolongs Survival in Low-Grade Glioma
  • Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
  • Personalizing Therapy for Patients with Multiple Myeloma
  • Targeting BCL2 with Venetoclax in Patients with Relapsed CLL
  • Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
  • Atezolizumab Shows Durable Response, Tolerability in Urothelial Carcinoma
  • Aprepitant Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Children
  • Bevacizumab for Advanced Lung Cancer Does Not Increase Risk for Hospitalization or Unexpected Toxicity
  • Daratumumab, an Anti-CD38 Monoclonal Antibody, Effective Treatment Option for Patients with Relapsed and/or Refractory Multiple Myeloma
The current treatment landscape for patients with high-risk localized prostate cancer is predominantly confined to a combination of androgen-deprivation therapy (ADT) plus radiotherapy, which has been shown to improve survival over radiotherapy alone.
We’ve compiled summaries and reviews of four studies dealing with treatments indicated for squamous-cell NSCLC, breast cancer, and neuroendocrine tumors.
We’ve compiled summaries and reviews of three studies dealing with treatments indicated for B-cell cancer, advanced thyroid cancer, and polycythemia vera.
  • Anti-CD19 CAR T-Cells Show Promise in B-Cell Cancer
  • Lenvatinib Prolongs Progression-Free Survival in Advanced Thyroid Cancer
  • Ruxolitinib More Effective Than Standard Therapy in the Treatment of Polycythemia Vera
Page 1 of 3
Results 1 - 10 of 30